AXON vs SEER

Key Takeaways

• Axon Enterprise (AXON) is a $40+ billion public safety technology platform with 33.5% revenue growth in fiscal 2025 and an expanding AI-powered product ecosystem, though its stock has pulled back from all-time highs reached in mid-2025.
• Seer, Inc. (SEER) is a micro-cap life sciences company pioneering deep, unbiased proteomics with $16.6 million in 2025 revenue, growing its installed instrument base 67% year-over-year but still operating at a significant net loss.
• The two companies operate in entirely different industries — public safety technology versus life sciences research tools — and differ dramatically in scale, with AXON generating roughly 167 times the revenue of SEER.
• AXON has demonstrated consistent profitability and recurring revenue growth, while SEER remains pre-profit and faces headwinds from uncertain NIH (National Institutes of Health) funding and cautious academic spending.
• SEER holds approximately $241 million in cash and investments against a market capitalization near $112 million, creating an unusual negative enterprise value that some investors view as a margin of safety.
• Risk profiles diverge sharply: AXON faces valuation compression risk after years of multiple expansion, while SEER faces adoption risk and ongoing cash burn in a constrained funding environment.

Introduction

Comparing Axon Enterprise (AXON) and Seer, Inc. (SEER) may seem unconventional at first glance — one is a dominant public safety technology company with a market capitalization exceeding $40 billion, while the other is a micro-cap proteomics firm valued near $112 million. Yet this comparison offers a useful lens through which to examine how different stages of corporate maturity, market positioning, and financial profiles translate into distinct risk-reward profiles. For traders and investors evaluating where to allocate capital, understanding the contrasts between an established high-growth compounder and an early-stage life sciences innovator can sharpen decision-making in today's dynamic market environment.

AXON Overview and Recent Performance

Axon Enterprise, Inc. has evolved far beyond its origins as the maker of TASER conducted energy devices. The company now positions itself as the operating system for public safety, integrating body cameras, in-car video systems, cloud-based digital evidence management, AI-powered report writing tools such as Draft One, drone and counter-drone technologies, and real-time situational awareness platforms. AXON operates through two segments: Software and Services, and Connected Devices. Its Software and Services segment has been a standout, with annual recurring revenue (ARR) reaching $1.3 billion as of late 2025, driven by strong demand for premium subscription tiers and AI-powered add-ons.

In recent months, AXON stock has experienced notable volatility. After reaching an all-time high above $870 in August 2025, shares pulled back meaningfully and have traded in a wide range between roughly $340 and $640 in 2026. The stock posted its first losing calendar year in nearly a decade in 2025, declining approximately 4%, which snapped a remarkable nine-year winning streak. Despite this, the underlying business has continued to deliver robust results, with full-year 2025 revenue reaching $2.78 billion — a 33.5% increase year-over-year — marking the seventh consecutive quarter of 30%-plus revenue growth. Recent acquisitions, including Fusus, Dedrone, Carbyne, and Prepared, have expanded AXON's total addressable market and strengthened its one-stop-shop value proposition for law enforcement and enterprise customers alike.

SEER Overview and Recent Performance

Seer, Inc. operates in a fundamentally different arena. The Redwood City, California-based life sciences company has developed the Proteograph Product Suite, an integrated solution that uses proprietary engineered nanoparticles, automation instrumentation, and data analysis software to enable deep, unbiased proteomics — the large-scale study of proteins in biological samples. This technology is designed to help researchers discover novel biomarkers and gain insights into disease mechanisms, with potential applications in diagnostics and precision medicine. SEER markets its products exclusively for research use and does not yet participate in clinical diagnostics.

In recent market activity, SEER has traded in a low range between approximately $1.55 and $2.41 per share, reflecting a market capitalization near $112 million. The company generated full-year 2025 revenue of $16.6 million, a 17% increase from the prior year, driven by growing adoption of its recently launched Proteograph ONE assay and SP200 automation instrument. Its installed base expanded 67% year-over-year to 82 instruments, and consumable kit volumes rose 69%. However, the company continues to operate at a substantial loss, reporting a net loss of $73.6 million for 2025. Importantly, SEER ended 2025 with approximately $241 million in cash, cash equivalents, and investments, providing a multi-year runway. The company's 2026 revenue guidance of $16 million to $18 million signals only modest growth expectations amid ongoing budgetary pressures affecting its academic and government customer base, including uncertainty surrounding NIH funding.

Trending AI Robots

For traders seeking to navigate markets with the assistance of sophisticated technology, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers across diverse strategies, timeframes, and risk profiles. Only the highest-performing and most contextually appropriate bots earn placement in the Trending AI Robots section, where users can browse bots with track records featuring annualized returns that have ranged from single digits to well over 50%, depending on strategy and market regime. Each bot operates with its own distinct trading style — from swing trading to longer-term trend following — and focuses on a specific set of stocks, ETFs, or forex pairs. Exploring the Trending AI Robots section can help traders identify algorithmically driven approaches that align with their individual objectives and risk tolerance.

Head-to-Head Comparison

The most immediate contrast between AXON and SEER is scale. AXON generates nearly $2.8 billion in annual revenue, employs thousands of people, and serves customers across international, federal, state, and local governments as well as commercial enterprises. SEER, by contrast, generated $16.6 million in 2025 and remains deeply unprofitable. This scale differential is reflected in market capitalizations of roughly $42 billion versus $112 million.

On the growth dimension, AXON has sustained revenue growth above 30% for multiple consecutive quarters — a remarkable feat for a company of its size — fueled by AI product adoption, international expansion, and enterprise market penetration. SEER has achieved meaningful percentage growth in its installed base and consumable volumes, but its absolute revenue growth remains modest, and its 2026 guidance implies only approximately 3% growth at the midpoint.

Risk factors diverge significantly. AXON's primary risk is valuation: trading at a forward price-to-earnings ratio substantially above industry averages, the stock is vulnerable to multiple compression if growth decelerates or sentiment shifts. SEER's risks are existential in nature — the company must meaningfully accelerate commercial adoption before its cash reserves deplete, all while navigating an uncertain funding environment for its core academic and government customers. On the other hand, SEER's negative enterprise value (cash exceeds market capitalization plus debt) offers a rare margin of safety not typically available in high-growth names.

Sector exposure also differs entirely. AXON sits at the intersection of aerospace and defense, SaaS (Software-as-a-Service), and AI, benefiting from secular trends in public safety digitization and government spending. SEER operates in the life sciences tools and diagnostics space, where adoption cycles are long, publication-driven, and heavily influenced by academic and government research budgets.

Tickeron AI Verdict

Based on observable factors such as trend consistency, revenue momentum, competitive positioning, and financial stability, Tickeron's AI-driven analytical framework would likely favor Axon Enterprise (AXON) in the current market environment. The company's established recurring revenue base, sustained above-30% top-line growth, expanding AI product ecosystem, and diversification across international, federal, and enterprise markets provide a foundation of relative predictability that algorithmic scoring models tend to reward. While AXON's elevated valuation warrants caution, its demonstrated ability to compound revenue and bookings at high rates over multiple years suggests a durable competitive advantage. Seer, Inc. (SEER) possesses intriguing long-term potential given its innovative proteomics platform and strong balance sheet relative to its market capitalization, but the combination of modest revenue scale, ongoing losses, conservative near-term guidance, and external funding headwinds creates a less favorable near-term trend profile. Probabilistically, AXON presents the more consistent and lower-uncertainty trajectory based on currently available data.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations